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Abstract
Background: Withholding live-attenuated vaccines in patients using interleukin (IL)-1 or IL-6 blocking agents is
recommended by guidelines for both pediatric and adult rheumatic diseases, since there is a risk of infection in an
immune suppressed host. However, this has never been studied. This retrospective, multicenter survey aimed to
evaluate the safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade.
Methods: We contacted physicians involved in the treatment of autoinflammatory diseases to investigate potential
cases. Patients were included if a live-attenuated vaccine had been administered while they were on IL-1 or IL-6
blockade.
Results: Seventeen patients were included in this survey (7 systemic juvenile idiopathic arthritis (sJIA), 5 cryopyrin
associated periodic syndrome (CAPS), 4 mevalonate kinase deficiency (MKD) and 1 familial Mediterranean fever (FMF).
Three patients experienced an adverse event, of which two were serious adverse events (a varicella zoster infection
after varicella zoster booster vaccination, and a pneumonia after MMR booster). One additional patient had diarrhea
after oral polio vaccine. Further, seven patients experienced a flare of their disease, which were generally mild. Eight
patients did not experience an adverse event or a flare.
Conclusion: We have described a case series of seventeen patients who received a live-attenuated vaccine while using
IL-1 or IL-6 blocking medication. The findings of this survey are not a reason to adapt the existing guidelines. Prospective
trials are needed in order to acquire more evidence about the safety and efficacy before considering adaptation of
guidelines.
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Background
Vaccines have contributed greatly to public health,
protecting children and adults from serious infectious
diseases [1]. Besides inactivated vaccines there are several
live-attenuated vaccines.
Autoinflammatory diseases, such as systemic juvenile
idiopathic arthritis (sJIA), familial Mediterranean fever
(FMF), mevalonate kinase deficiency (MKD), cryopyrin
associated periodic syndrome (CAPS) and tumor necrosis
factor (TNF)-receptor associated periodic syndrome
(TRAPS) exhibit systemic inflammation or organ specific
inflammation caused by dysregulation of the innate
immune system. Interleukin (IL)-1 blockade (anakinra,
canakinumab and rilonacept) and IL-6 blockade
(tocilizumab) have greatly improved the outcome of these
patients [2]. However, patients with autoinflammatory
diseases potentially face long-term or lifelong immunosup-
pression thus raising the dilemma if and when vaccinations
could be given.
Although vaccination is generally considered safe in the
healthy population, existing guidelines for both pediatric
and adult rheumatic diseases recommend to withhold live-
attenuated vaccines in patients using IL-1 or IL-6 blocking
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agents, because of lack of safety data and the (theoretical)
risk of introducing infection in an immune suppressed host
[3–5]. On the other hand, patients with autoinflammatory
diseases might especially benefit from protection against
infectious diseases, as the immunosuppressive therapy ren-
ders them more susceptible to infections [6, 7]. In clinical
practice, vaccination can be considered on a case-to-case
basis weighing the risk of natural infection versus the risk
of vaccination, e.g. measles mumps and rubella (MMR)
vaccination during measles outbreaks or yellow fever
vaccine before travelling to endemic regions.
In this retrospective survey, we aimed to evaluate the
safety and efficacy of live-attenuated vaccines in patients
using IL-1 or IL-6 blockade.
Methods
Via the Paediatric Rheumatology European Society and
the International Society for Systemic Auto Inflammatory
Diseases pediatric and adult rheumatologists and immu-
nologists were contacted by e-mail in January 2016 in
order to recruit potential cases. A reminder was sent up
to three times, if no response was obtained. Patients were
included if they had received a live-attenuated vaccine
while using IL-1 blockade or IL-6 blockade.
Ethical approval was obtained by the institutional ethical
committee in accordance with local ethical regulations; the
survey was conducted in accordance with the ethical prin-
ciples of the declaration of Helsinki. Written informed
consent was obtained from the patient or the legal guard-
ians in case of minors according to local requirements.
Demographic and clinical data were collected by local
physicians and were anonymized. Adverse events were
categorized as adverse events and serious adverse events.
Serious adverse events were defined as events leading to
death, life-threatening events, events leading to
hospitalization, prolonged hospitalization and events lead-
ing to severe and/or permanent disability [8]. A flare was
defined as the presence of any symptoms of the disease,
e.g. fever, rash, abdominal pain and diarrhea.
Results
In total 85 physicians from 23 countries were contacted.
In total, seventeen patients were included: 7 sJIA, 5
CAPS, 4 MKD and 1 FMF. The median age at vaccin-
ation was 9 years (1–58 years), 11 patients were female.
Most patients received a booster vaccine for MMR, but
patients also received varicella zoster, yellow fever and
oral polio vaccines. Patient characteristics are listed in
Table 1. The patients are discussed in more detail below.
Adverse events
Three patients reported an adverse event after vaccin-
ation, of whom two were categorized as severe due to
the need for hospitalization.
Patient 1 was a seven-year-old girl with sJIA, who was
treated with multiple immunosuppressive agents at the
same time, including prednisone, methotrexate (MTX),
thalidomide, leflunomide and anakinra. Sixteen days
after she received a varicella zoster booster vaccination,
she developed vesicles on her trunk and a few on her
scalp and extremities. The diagnosis of varicella zoster
infection was made on the clinical phenotype; the virus
could not be isolated. Because of suspected varicella in an
immunocompromised host, she was admitted to hospital
for 4 days and was discharged with a 10-day course of
intravenous acyclovir. As there was no known exposure to
other varicella cases, the infection in this child was consid-
ered to be caused by the vaccination itself.
Patient 2 suffered from sJIA and was treated with
canakinumab. She was accidentally vaccinated with
MMR booster by the vaccination campaign in Turkey.
One week after vaccination she was diagnosed with
pneumonia, which was confirmed by X-ray. As it was
considered to be a bacterial pneumonia, treatment with
cefuroxime axetil was started. The patient was hospital-
ized for 5 days. Besides the pneumonia, she had a sJIA
flare with fever and rash during the same period. This
flare was treated with low-dose prednisone with good
response. The impression of the physicians in charge was
that this was a flare of her sJIA. Although extremely un-
likely, the coincidence of fever, rash and pneumonia could
also be ascribed to measles, introduced by vaccination.
The last patient (patient 3) with an adverse event was a
sJIA patient treated with tocilizumab. One week after vac-
cination with oral polio vaccine, the patient experienced
diarrhea, which was treated with oral fluid replacements,
co-trimoxazol and probiotics. This adverse event was
thought to be caused by the vaccine, especially since other
family members did not suffer from diarrhea.
Flares
In total seven patients reported a flare of their disease after
vaccination. A MKD patient (patient 4) received 100 mg
anakinra daily, which was stopped 3–4 days before booster
vaccination with varicella zoster and restarted 1 day after
vaccination. He experienced fever after vaccination. Since
the fever was thought to be caused by a flare, the patient
was treated with the normal dose of anakinra. Patient 5
used anakinra (150 mg) during MKD flares only, since the
disease was relatively quiescent. The days before and after
vaccination with varicella zoster, anakinra was not adminis-
tered. After vaccination he experienced fever, which was
treated with anakinra. Patient 6 was 4 years old when she
received her first MMR and varicella zoster vaccines. Her
disease was incompletely controlled under treatment with
canakinumab 4 mg/kg every 6 weeks. Canakinumab was
stopped 3 months before and restarted 3 months after
vaccination. Before vaccination she experienced low grade
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fevers every week. After vaccination she had a mild flare
with fever, vomiting, diarrhea and headache. This flare was
treated with acetaminophen and ibuprofen. Patient 7 was
treated with canakinumab due to colchicine resistant FMF.
Besides FMF, she also suffered from inflammatory bowel
disease. The vaccination with MMR booster was adminis-
tered accidentally by the primary health service in Turkey.
Due to this vaccination the next dose of canakinumab was
withheld; the following dose was given 2 months after vac-
cination. One week after vaccination the patient had an
FMF attack with fever and abdominal pain, which led to
hospitalization. During hospitalization she was treated with
low-dose prednisone (2.5 mg/day) and colchicine (0.5 mg/
day) with good response. After 8 days she was discharged
in good condition.
In another patient (patient 8) who suffered from sJIA,
anakinra was stopped 2 days before and restarted 3 days
after vaccination. After MMR booster vaccination she ex-
perienced a mild flare with some exanthema, but without
fever, which was probably due to the stop of anakinra.
This flare did not require any additional treatment.
Patient 9 was a young boy with Down syndrome and
sJIA complicated by macrophage activation syndrome.
He was initiated on tocilizumab treatment at a very
young age, before experiencing varicella zoster infection;
therefore, he was vaccinated with a first varicella zoster
vaccine, in order to acquire immunity in a controlled
setting. After vaccination he suffered from a mild flare
with subfebrile temperature, exanthema and malaise.
After this flare, the physician and parents decided not to
repeat varicella vaccination.
Patients without flares or adverse events
Eight patients did not experience a flare or an adverse
event. Patient 10 suffered from Chronic Infantile Neuro-
logical Cutaneous Articular (CINCA) syndrome, the most
severe form of CAPS, which was treated with anakinra. At
the age of 12 years he received MMR vaccination as a
routine administration of the booster vaccine. Treatment
with anakinra was stopped 3 days before vaccination and
restarted 2 weeks afterwards. He did not have any adverse
events. Patient 11 who had MKD was in partial remission
at the time of vaccination. The treatment of anakinra was
stopped 3 days before vaccination and restarted 4 weeks
afterwards. The last two patients were Dutch sJIA patients
with inactive disease on anakinra (patient 12) or toci-
lizumab and MTX (patient 13). They received the MMR
booster vaccine through the national vaccination program,
and reported no symptoms afterwards. Patients 14–16
concerned a mother and two daughters all suffering from
CAPS, which was treated with anakinra. In order to be
protected against yellow fever during travel, they were all
vaccinated without any problems. The three of them
suspended anakinra for 3 days prior and 3 days after
vaccination. The last patient (patient 17) was treated with
canakinumab and received a yellow fever vaccination. The
vaccine was given 8 weeks after the last dose and the next
dose was given 3 weeks after vaccination.
Discussion
This survey describes the safety of live-attenuated vaccine
in a case series of patients using IL-1 or IL-6 blocking
medication. The seventeen patients in our series reported
three adverse events, of which two were categorized as
severe, and seven flares, while eight patients did not report
any complaints after vaccination. Although adverse events
occurred soon after vaccination, coincidence cannot be
ruled out. Flares were associated with discontinuation of
IL-1 blockade before vaccination in four of the seven
patients.
The retrospective design of this survey comes with a
number of limitations. Due to this design, information
on antibody titers is lacking as these are not routinely
measured after vaccination. Therefore, we cannot draw
any conclusions about the vaccine efficacy. Further, the
small number of patients and the variety in diseases, age,
medication and vaccines hampers conclusions on the
safety of live-attenuated vaccines in general. Immuno-
logical characterization of patients before or after
vaccination was not possible due to the retrospective
design. The small number and the heterogeneity of the
group precluded statistical analysis. The small number
of patients included, however, reflects the reluctance of
physicians to administer live-attenuated vaccines to
patients using these biologicals.
A substantial number of patients in this series were
vaccinated inadvertently through national vaccination
programs, which has also led to a lack of follow-up data
since patients were not monitored by their physician
during and after vaccination. Live-attenuated vaccines
cannot be considered entirely safe in patients using IL-1
or IL-6 blockade since up to three patients experienced
an adverse event, while seven patients experienced a
flare to some extent. This should be taken into consider-
ation before administering live-attenuated vaccines in
patients using IL-1 or IL-6 blockade.
At least one adverse event was considered to be
caused by the micro-organism of the vaccine (patient 2,
varicella). However, rash and in particular vesicles are
also seen in 3% of healthy children after vaccination with
varicella zoster vaccine [9]. Thus, the reported vesicles
after vaccination might also be explained by a common
vaccination reaction. In the two other patients with an
adverse event it cannot be established with certainty that
vaccination led to the symptoms of these patients, as
pneumonia and diarrhea are common infections in
childhood.
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In our series, three of four MKD patients reported a
flare after vaccination. It is already known that vaccination
is a well-known trigger of fever episodes in MKD [10].
However, in these three patients the biological was
stopped around the vaccination, as was the case in a child
with another disorder who flared. The discontinuation
might have contributed to the flares as well. Further, fever
and rash are also quite common symptoms after vaccin-
ation in healthy children and adults. For example, fever is
noted in 10–15% of children receiving varicella zoster vac-
cine [9]. After MMR vaccination 17% of healthy children
and adults reported fever and 5% mentioned a rash [11].
Several studies have described the safety and efficacy of
inactivated vaccines in patients using IL-1 blocking agents
[12–15]. Two studies on canakinumab showed no differ-
ence in antibody titers between groups on canakinumab
and subjects not on canakinumab [12, 13]. A study on
anakinra also did not show a significant difference in
antibody responses [14].
The data on disease flares and adverse events after
vaccination are conflicting. In the phase-III trial of canaki-
numab in 109 CAPS patients, fifteen patients received
influenza vaccination, five patients pneumococcal vaccin-
ation and one patient received MMR vaccine [16]. None of
these patients reported an adverse event. Also in the study
of 17 CAPS patients on canakinumab, no flares were
described. Adverse events included predominantly upper
respiratory tract infections. However, a recent study
showed that CAPS patients treated with canakinumab
reacted severely after pneumococcal vaccination [17].
Twelve of 18 patients who received pneumococcal immu-
nizations developed vaccine reactions (fever, swelling,
erythema, pain), usually within hours after vaccination. Re-
actions lasted up to 3 weeks. In two patients pneumococcal
vaccination triggered CAPS reactivation with systemic
inflammation.
Conclusions
In conclusion, we have described a retrospective case
series of seventeen patients who received live-attenuated
vaccines while using IL-1 or IL-6 blocking medication.
The current data are insufficient to draw any conclusions
about the safety of these vaccines in patients using IL-1/
IL-6 blockade. Therefore, more safety and efficacy data
are needed before considering adaptation of guidelines.
Until that time, physicians should still balance the risk of
natural infection versus the risk of vaccination, including
disease flares and other adverse events, for each individual
patient.
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